Presentation and Management of Silicone Lymphadenopathy: A Single Institutional Retrospective Cohort Study

• DOI: 10.1007/s00266-024-04649-z
• Publication Date: 2025-01-10T17:44:56Z
• Authors: Anshumi Desai; Taylor Smartz; Orel Tabibi; Peter A. Borowsky; Kashyap Komarraju...; Devinder P. Singh; Susan B. Kesmodel; Kristin E. Rojas; Juan R. Mella-Cat...
• Keywords: Presentation (obstetrics)

Abstract Introduction Silicone Lymphadenopathy (SL) is a complication of breast implants that involves migration silicone to nearby soft tissue/lymph nodes. Data on its clinical features and management scarce. We aimed identify the presentation SL. Methods A single-institution retrospective cohort study was conducted from our institutional imaging system where search terms “Silicone lymphadenopathy”, “silicone adenitis” adenopathy” were used patients with SL (January 2016–September 2023). Patient demographics, features, findings, pathological investigation, treatment obtained medical records. Results Of 52 SL, augmentation accounted for 90.4% implant placements. All had placed at some time. significant portion (69.3%) asymptomatic, while 7.7% non-tender lymphadenopathy, 19.2% experienced painful 1.9% presented mixed symptoms. Implant rupture observed in 88.7% cases; 13.0% intracapsular, 26.1% extracapsular, 15.2% both, unknown 45.7%. Axillary nodes most commonly involved (86.5%), ultrasonography detect (80.7%). Biopsy performed 17.3% cases, confirming benign pathology all cases. No required surgical excision lymph Conclusion Most are asymptomatic managed observation. intervention should be reserved those abnormal or persistent Evaluation lymphadenopathy essential exclude malignancy history cancer. Level Evidence III This journal requires authors assign level evidence each article. For full description these Evidence-Based Medicine ratings, please refer Table Contents online Instructions Authors www.springer.com/00266 .